Cytiva Cell datasheets catalogs app notes

  1. Using Automated Spinoculation For CAR T Cell Lentiviral Transduction 2/26/2024

    There is a growing demand for closed and automated lentiviral transduction steps in CAR T cell therapy workflows. Learn about a potential solution to address this unmet need.

  2. Standardize Scale-Up And Reduce Time To Market With Mixing Cartridges 7/21/2023

    Despite the momentum of the RNA-LNP therapeutic market, significant manufacturing challenges remain. However, the right mixing could solve three of these key challenges regarding instrumentation.

  3. Understanding The Microfluidic Platforms For Scaling Nanoparticle Production 10/13/2022

    Learn about the benefits of microfluidics for nanoparticle production over traditional methods as well as scaling nanoparticle production for clinical or industrial use.

  4. Biacore™ SPR Systems For Titer Analysis Of Adeno-Associated Virus 10/13/2022

    We describe the performance of two assays for titer analysis of adeno-associated virus (AAV), serotype 2 and serotype 5, based on surface plasmon resonance (SPR).

  5. AAV Production In Suspension HEK293 Cells With Single-Use Bioreactors 10/13/2022

    Explore how we expanded HEK293/HEK293T suspension cells from small cell culture (20 mL) in shake flasks up to a 10 L culture in a benchtop Xcellerex™ XDR-10 single-use bioreactor system.

  6. Recombinant Adeno-Associated Virus Type 5 Production Process 10/12/2022

    Learn about a scalable process for the production of rAAV using triple plasmid transfection of suspension cells in an animal-derived component-free medium.

  7. Apheresis Variability Control In Cell Therapy Manufacturing 7/25/2022

    Explore our best practices for apheresis collection and obtention of enriched product for cell therapies.

  8. Automating And Optimizing The Cell Harvesting Process 7/25/2022

    Discover how we automate the process of optimizing cell harvesting and further minimize the potential for cell loss during wash steps.

  9. Natural Killer Cells Manufacturing 7/22/2022

    Follow the feasibility of xeno‑free NK cell expansion, closure of key unit operations, and how future work could focus on fine‑tuning each step to generate a robust, scalable process.

  10. Optimizing Recovery On The Sepax™ Cell Processing System 7/21/2022

    Using a model T-cell line, we demonstrate the impact of varying rinse volume, intermediate volume, and manual extraction parameters on overall cell recovery with a final product dose volume of 20 mL.